Cetuximab in first-line treatment of metastatic colorectal cancer in a real-life setting: Preliminary results of the EREBUS cohort.

被引：0
|
作者：
Smith, Denis
Rouyer, Magali
Mitry, Emmanuel
Monnereau, Alain
Cunha, Antonio Sa
Bignon, Emmanuelle
Le Monies, Alise
Jove, Jeremy
Noize, P.
Moore, Nicholas
Fourrier-Reglat, Annie
机构：
[1] Univ Hosp, Med Oncol, Bordeaux, France
[2] Univ V Segalen, Serv Pharmacol, Bordeaux, France
[3] Inst Curie, St Cloud, France
[4] Inst Bergonie, Bordeaux, France
[5] Chirurg Digest Hop Haut Leveque, Pessac, France
[6] Univ Bordeaux, Serv Pharmacol, Bordeaux, France
[7] Serv Pharmacol, Bordeaux, France
[8] Univ Victor Segalen, Bordeaux, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.621
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
621
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
  • [42] IMPACT ON QUALITY OF LIFE OF CETUXIMAB PLUS FOLFIRI IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE CRYSTAL TRIAL
    Lang, I
    Aleknaviciene, B.
    Zolotukhin, S.
    Komissarenko, V
    Garcia-Alfonso, P.
    Jurga, L.
    Moiseyenko, V
    Filipczyk-Cisarz, E.
    Zubel, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 24
  • [43] Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL).
    Lang, I.
    Zaluski, J.
    Changchien, C. R.
    Makhson, A.
    Pinter, T.
    D'Haens, G.
    Lim, R.
    Nippgen, J.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 159S - 159S
  • [44] Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal CA.
    Rougier, P
    Raoul, JL
    Van Laethem, JL
    Peeters, M
    Husseini, F
    Brezault, C
    Cals, L
    Vedovato, JC
    Mueser, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 248S - 248S
  • [45] Optimizing the first-line treatment for metastatic colorectal cancer
    Cherri, Sara
    Oneda, Ester
    Zanotti, Laura
    Zaniboni, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [46] Optimizing the first-line treatment for metastatic colorectal cancer
    Ciardiello, Davide
    Petrillo, Angelica
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] Cetuximab observational study as first-line therapy in patients with metastatic colorectal cancer
    Itabashi, Michio
    Tani, Kimitaka
    Muro, Kei
    Masuishi, Toshiki
    Ohashi, Yasuo
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer
    Moosmann, Nicolas
    Heinemann, Volker
    CLINICAL COLORECTAL CANCER, 2008, 7 (02) : 110 - 117
  • [49] Outcomes of Chemotherapy plus Cetuximab as First-line Treatment in Patients with Metastatic, Recurrent, Unresectable Head and Neck Cancers: Real-life Data
    Yazilitas, Dogan
    Sahinli, Hayriye
    Saylam, Guleser
    Imamoglu, Goksen Inanc
    Korkmaz, Mehmet Hakan
    Bayir, Omer
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (04): : 469 - 473
  • [50] NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy
    Rinaldi, Fiona
    George, Elisabeth
    Adler, Amanda I.
    LANCET ONCOLOGY, 2012, 13 (03): : 233 - 234
12345